anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SERIOUS INFECTIONS

Patients treated with adalimumab products including Adalimumab-aacf are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue Adalimumab-aacf if a patient develops a serious infection or sepsis. Reported infections include:

  * Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-aacf use and during therapy. Initiate treatment for latent TB prior to Adalimumab-aacf use.
  * Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti- fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
  * Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.



Carefully consider the risks and benefits of treatment with Adalimumab-aacf prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Adalimumab-aacf, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2)].
The invention relates to application of a jasmine leaf extract. The content of gardenoside in the jasmine leaf extract is 8-15 percent. The invention also relates to application of the jasmine leaf extract in preparation of medicines with functions of clearing away heat and toxic materials, moistening dryness and decreasing internal head, and protecting the liver and benefiting the bile. The invention further relates to application of the jasmine leaf extract in preparation of anticancer medicines. Because jasmine leaves and jasmine fruits have similar pharmacological activities and main active components, the jasmine leaves can replace the jasmine fruits to be used in production of relevant medicines. Because the yield of the jasmine leaves is above 25 times of that of the jasmine fruits, when the jasmine leaves are used for producing the relevant medicines, the production cost can be greatly lowered; on the other aspect, because the jasmine leaves are rich in sources, and can be supplied in full year, the extract can be produced in full year, so that the rate of equipment utilization and the cash conversion cycle are greatly improved, and the production cost and risk are reduced.
BACKGROUND: Individuals with shoulder pathologies frequently report sleep problems. Improving sleep quality is a treatment focus of shoulder arthroplasty. So far, it is unclear whether altered anatomy and biomechanics in reversed total shoulder arthroplasty affect sleep quality in the long term. In addition to a subjective evaluation, a reliable assessment can be obtained by recording objective sleep parameters. With the help of actigraphy, body movements are registered and divided into active and inactive phases by means of threshold values. Thanks to the valid correspondence with waking and sleeping phases, the calculation of objective sleep parameters is successful.
OBJECTIVES: The aims of the study were to investigate whether objective sleep parameters differ in persons with reversed total shoulder arthroplasty (RTSA) 1 year postoperatively compared to a healthy control group and to explore what the reasons are.
MATERIAL AND METHODS: The present work is an exploratory cross-sectional study with one measurement time point. 29 study participants (15 in the RTSA-group, 14 in the control group) collected objective sleep parameters and body position data during seven nights using actigraphy. The Mann-Whitney-U test was used for the mean comparison of sleep parameters. In addition, reasons for wakefulness were explored.
RESULTS AND CONCLUSIONS: The groups showed no significant differences in all objective sleep parameters with nearly identical sleep efficiency (p = 0.978). In the RTSA-group, 11% lay on the operated side and 65% on the back. This is just above the significance level compared to the control group with 45% in the supine position (p = 0.056). The increased use of the supine position could promote sleep-related medical conditions such as sleep apnoea and requires further research.
BACKGROUND: Autologous breast reconstruction offers superior long-term patient reported outcomes compared with implant-based reconstruction. Universal adoption of free tissue transfer has been hindered by procedural complexity and long operative time with microsurgery. In many specialties, co-surgeon (CS) approaches are reported to decrease operative time while improving surgical outcomes. This systematic review and meta-analysis synthesizes the available literature to evaluate the potential benefit of a CS approach in autologous free tissue breast reconstruction versus single-surgeon (SS).
METHODS: A systematic review and meta-analysis was conducted using PubMed, Embase, and MEDLINE from inception to December 2022. Published reports comparing CS to SS approaches in uni- and bilateral autologous breast reconstruction were identified. Primary outcomes included operative time, postoperative outcomes, processes of care, and financial impact. Risk of bias was assessed and outcomes were characterized with effect sizes.
RESULTS: Eight retrospective studies reporting on 9,425 patients were included. Compared with SS, CS approach was associated with a significantly shorter operative time (SMD -0.65, 95% confidence interval [CI] -1.01 to -0.29, p < 0.001), with the largest effect size in bilateral reconstructions (standardized mean difference [SMD] -1.02, 95% CI -1.37 to -0.67, p < 0.00001). CS was also associated with a significant decrease in length of hospitalization (SMD -0.39, 95% CI -0.71 to -0.07, p = 0.02). Odds of flap failure or surgical complications including surgical site infection, hematoma, fat necrosis, and reexploration were not significantly different.
CONCLUSION: CS free tissue breast reconstruction significantly shortens operative time and length of hospitalization compared with SS approaches without compromising postoperative outcomes. Further research should model processes and financial viability of its adoption in a variety of health care models.
The progression of small bowel ischemia-reperfusion (IR) injury causes cells in the intestinal tract to undergo necrosis, necessitating surgical resection, which may result in loss of intestinal function. Therefore, developing therapeutic agents that can prevent IR injury at early stages and suppress its progression is imperative. As IR injury may be closely related to oxidative stress, antioxidants can be effective therapeutic agents. Our silicon (Si)-based agent, an antioxidant, generated a large amount of hydrogen in the intestinal tract for a prolonged period after oral administration. As it has been effective for ulcerative colitis, renal failure, and IR injury during skin flap transplantation, it could be effective for small intestinal IR injury. Herein, we investigated the efficacy of an Si-based agent in a mouse model of small intestinal IR injury. The Si-based agent suppressed the apoptosis of small intestinal epithelial cells by reducing the oxidative stress induced by IR injury. In addition, the thickness of the mucosal layer in the small intestine of the Si-based agent-administered group was significantly higher than that in the untreated group, revealing that Si-based agent is effective against small intestinal IR injuries. In the future, Si-based agents may improve the success rate of small intestine transplantation.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic preventing make up from coming off, and having a good make up maintenance.  <P>SOLUTION: The cosmetic is provided by incorporating with blending specific polyurethane particles in a cosmetic base agent. The specific polyurethane particles consist of polyurethane particle main bodies and a hydrophilic silica fine particles covering the surface of the particle main bodies. The polyurethane particle main bodies are obtained by three dimensionally polymerizing an isocyanate terminal urethane prepolymer obtained by the reaction of a polyisocyanate component with a polyol component containing a polytetramethylene glycol, by a polyfunctional amine having ≥3 functions. The polyurethane particles are obtained by the spray drying of mixed aqueous dispersion obtained by dispersing hydrophilic silica fine particles and the three-dimensionally polymerized polyurethane spherical materials in water, by using a spray-drying machine.  <P>COPYRIGHT: (C)2010,JPO&INPIT
OBJECTIVE: To explore the molecular mechanism by which FEZF1-AS1 overexpression promotes progression of nonsmall cell lung cancer (NSCLC) via the miR-130a-5p/CCND1 axis.
METHODS: TCGA database was used to analyze FEZF1-AS1 expression levels in NSCLC. FEZF1-AS1 expression was detected by qRT-PCR in clinical specimens of NSCLC tissues and NSCLC cell lines, and its correlation with clinical features of the patients were analyzed. The binding sites of FEZF1-AS1 with hsa-miR-130a-5p and those of hsa-miR-130a-5p with CCND1 were predicted. CCK8 assay, clone formation assay, scratch assay, and Transwell assay were employed to examine the effects of FEZF1-AS1 knockdown and hsa-miR-130a-5p inhibitor on proliferation, invasion, and migration abilities of lung cancer cell lines. Dual luciferase assay was used to verify the binding of FEZF1-AS1 with hsa-miR-130a-5p and the binding of hsa-miR-130a-5p with CCND1. Western blotting was performed to detect the changes in CCND1 protein expression level in H1299 and H358 cells following FEZF1-AS1 knockdown and treatment with hsa-miR-130a-5p inhibitor.
RESULTS: FEZF1-AS1 was highly expressed in NSCLC tissues in close correlation with lymph node metastasis and also in H1299 and H358 cell lines (all P < 0.05). FEZF1-AS1 knockdown obviously reduced proliferation, migration, and invasion abilities of NSCLC cells (P < 0.05). Dual luciferase assay confirmed the binding of hsa-miR-130a-5p with FEZF1-AS1 and CCND1 (P < 0.05), and hsa-miR-130a-5p inhibitor significantly inhibited proliferation, migration, and invasion of NSCLC cells (P < 0.05). FEZF1-AS1 knockdown significantly reduced CCND1 protein expression in NSCLC cells, and this effect was strongly inhibited by treatment with hsa-miR-130a-5p inhibitor (P < 0.05).
CONCLUSION: FEZF1-AS1 is highly expressed in NSCLC tissue in close correlation with lymph node metastasis to promote cancer progression through the miR-130a-5p/CCND1 axis.
Common mental disorders (CMDs) are highly prevalent in workplace settings, and have become a significant public health challenge. This study aims to assess the effectiveness of PRATICAdr 2.0, a web application facilitated by a Return-to-Work Coordinator (RTW-C), with a focus on reducing sick leave duration and preventing relapse in individuals with CMDs. PRATICAdr 2.0 designed to enhance collaboration among Return-to-Work (RTW) stakeholders and provide systematic support throughout the RTW process, is evaluated in a randomized control trial (RCT). As part of the RCT, a total of 80 sick leave employees from 4 large public health organizations (n=80, 40 from the experimental group and 40 from the control group) will be recruited. The control group receives usual services offered by a RTW-C to sick leave employees, while the experimental group receives RTW-C services plus the use of PRATICAdr 2.0. Participants will be randomly assigned to either the PRATICAdr 2.0 experimental group or the control group using computerized stratified randomization based on age, site, and sex (sealed envelope method). Participants will complete a series of online questionnaires at several following time points. Survival analyses were used to compare sick leave durations and relapses between the experimental group (PRATICAdr with RTW-C), and control groups (RTW-C only). Mixed linear models were used to observe changes in clinical symptoms over time, especially for the experimental group.
Healthy diet based on mediterranean guidelines with specific recommendation of fish intake (3-4 servings/week of fresh or frozen fish or shellfish where at least 1-2 servings will be in the form of canned fish). A selection of canned fish (tuna, sardine, salmon and mackerel) will be administered to each volunteer for the duration of the study.
Compositions and methods for the diagnosis and treatment of diseases that are associated with imprinting are provided. Such compositions and methods are useful in restoring a normal pattern of imprinting to cells. The compositions comprise pharmacological agents that are involved in imprinting and can be used in preventive and therapeutic methods to restore a normal pattern of imprinting. Such agents are capable of restoring a normal pattern of imprinting to cells. Further methods of the invention include means for identifying pharmacological compounds that exert their effect by restoring normal imprinting to abnormally imprinted chromosomes and genes. Additionally, the invention could also be used to identify new compounds that exert their effect by restoration of normal imprinting to diseased tissues that exhibit underlying abnormal imprinting.
PURPOSE: A composition and a health functional food containing a Piperis Longi Fructus extract are provided to suppress the growth of pancreatic cancer cells, and to effectively treat pancreatic cancer. CONSTITUTION: A composition and a health functional food for treating a pancreatic cancer contain a Piperis Longi Fructus extract as an active ingredient. The extract is an organic solvent extract prepared using ethanol. The extract is prepared at 50 deg. C. for 24 hours, and dried and concentrated using 45 deg. C. The composition contains a pharmaceutically acceptable carrier or diluents. The pancreatic cancer is pancreatic ductal adenocarcinoma. [Reference numerals] (AA) Relative cellular viability
Side effects reported with the administration of hydroxyzine pamoate are usually mild and transitory in nature.

Dry mouth. Anticholinergic:

Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses. Central Nervous System:

In post-marketing experience, the following additional undesirable effects have been reported: allergic reaction, headache, hallucination, pruritus, rash, urticaria. Body as a Whole:Nervous System:Psychiatric:Skin and Appendages:
Patients receive anetumab ravtansine IV over 1 hour on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE:An analgesic and sedative comprising uracil as an active ingredient. CONSTITUTION:Uracil has low toxicity and shows analgesic and sleep prolonging action, so it is useful as an analgesic and sedative. It is also useful for remedying various kinds of diseases caused by stress as an antistress agent. When it is prepared as a drug, uracil may be in the form of a salt with an  organic or inorganic acid, and is medicated orally or parenterally. Tablets, capsules, pills, powder, granules, etc. for oral medication are pharmaceutically prepared by using properly starch, talc, gelatin, etc., and injections, etc. for parenteral medication are pharmaceutically prepared in the presence of sodium acetate, sodium benzoate, ethylenediamine, etc. It can also be used as suppositories  and ointments. A daily dose for adult is 100-5,000mg by oral medication and  10-1,500mg by parenteral medication.
The invention relates to an actuation system and method for an implantable infusion pump. In an example, a working fluid is placed in an actuator. Upon actuation, the working fluid is driven into a piston cylinder. Upon deactuation, the actuator draws the fluid from the cylinder through a restrictor at a rate dictated by the motivating force, fluid viscosity, and restriction. Driving of the piston may produce a bolus dosage or fill a supplemental flow chamber for subsequent delivery. The exemplary system may be configured by selecting a fluid volume and a viscosity. These, in combination, produce a prescribed fluid delivery rate (or recharge rate) and cumulative flow volume provided to a patient over a time period or in a bolus dose. The system may also be configured to limit the total dosage of a bolus injection, or the rate of a supplemental dosage. In this manner, the system is safe, preventing overdose.
The PTPRQ gene has been identified as one of the genes responsible for non-syndromic sensorineural hearing loss (SNHL), and assigned as DFNA73 and DFNB84. To date, about 30 causative PTPRQ variants have been reported to cause SNHL. However, the detailed clinical features of PTPRQ-associated hearing loss (HL) remain unclear. In this study, 15,684 patients with SNHL were enrolled and genetic analysis was performed using massively parallel DNA sequencing (MPS) for 63 target deafness genes. We identified 17 possibly disease-causing PTPRQ variants in 13 Japanese patients, with 15 of the 17 variants regarded as novel. The majority of variants identified in this study were loss of function. Patients with PTPRQ-associated HL mostly showed congenital or childhood onset. Their hearing levels at high frequency deteriorated earlier than that at low frequency. The severity of HL progressed from moderate to severe or profound HL. Five patients with profound or severe HL received cochlear implantation, and the postoperative sound field threshold levels and discrimination scores were favorable. These findings will contribute to a greater understanding of the clinical features of PTPRQ-associated HL and may be relevant in clinical practice.
The present invention relates to a method for preparing a Chinese medicinal vein injection for treating cancers. Tumors and Cancers are common diseases and frequently encountered diseases; the existing medicines for treating various tumors and cancers have partial curative effects but are incapable of radically treating tumors and cancers; the existing treating methods such as operations, chemotherapy and diathermy can not radically treat tumors and cancers either. The present invention provides a method for preparing a vein injection capable of preventing and treating tumors and cancers. The injection is prepared by using musk, bezoar, leech, etc. as raw materials and specially processing the raw materials. The raw materials are decocted in water; filter liquor is collected and concentrated into paste; the paste is diluted by distilled water and sterilized and filled in a bottle (2 ml) at a high temperature. The injection has the advantages of no toxicity or side effect, short treatment period and good curative effect; the cure rate of the injection to liver cancer and lung cancer is 50%, and the effective rate to other cancers is 40%.
Method for preparing new espiro (dihydrobenzofuranpiperidines and pyrolroline) of formula (I), or a salt of addition of acid of them, pharmaceutically acceptable. X may be an atom of hydrogen or various types of radicals, "n" is the whole 1 or 2. The method is to hydrogen a compound of formula (II), where r is bencilo and provides a compound where r is hydrogen. Also understands to react a compound like the above, where r is hydrogen with different types of halures, providing the desired compound. This composite can also be obtained by reduction. This product has an application as analgesic, tranquilizing and as an intermediate for them. *formula* (Machine-translation by Google Translate, not legally binding)
This study is conducted as a randomized controlled clinical trial regarding the use of two different marketed collagen membrane with freeze-dried bone allograft (FDBA) in treatment of periodontal intrabony defects. Collagen membrane acts as a barrier that prevents soft tissue (gums) from growing into the area where bone regeneration is desired. This allows the bone and other necessary tissues to regenerate more effectively. Sutures are removed 14 days after the surgery. Patients are then followed up at 5, 13- and 27-weeks post-surgery for Gl, PI, GR, PPD, and CAL to evaluate the tissue condition. The cone beam computed tomography (CBCT) and the X-ray radiographic evaluation will be assess in this study twice before and after treatment week 27 on the investigational site. And all subjects will receive intra-oral scanning with an intra-oral scanner at baseline and week 5, 13, 27 follow-up visits to assess the gingival tissue thickness and gingival tissue volume change. Safety data and adverse events would be recorded throughout the study.
665,367. Penicillin gels. BRISTOL LABORATORIES, Inc. Jan. 18, 1949 [Feb. 27, 1948], No. 1423/49. Class 81 (i). A non-aqueous, homogeneous, stable, injectable, therapeutic gel is prepared by adding an aluminium stearate in an amount not exceeding 10 per cent by weight of the gel to a non-toxic, non-rancid, bland, vegetable oil in an amount sufficient, when heated together with the oil, to produce such gel, heating the mixture to a temperature at which the aluminium stearate is homogeneously dispersed in the oil with the formation of the gel, and thereafter admixing therein at a temperature below that at which appreciable loss of potency occurs a non-toxic salt of penicillin. Preferably 2 to 5 per cent, especially 4 per cent, of the aluminium stearate is used. The temperature at which the stearateoil mixture is heated is 130 to 200‹ C., the higher temperature being used for the higher stearate concentrations. Sodium or potassium penicillin is incorporated at temperatures below 170‹ C., preferably 150‹ C., and calcium penicillin at below 70‹ C. Specified vegetable oils are peanut, persic, corn, cotton seed, sesame, soyabean, raw linseed, palm, teaseed, olive and mixtures thereof. The aluminium stearate may be the mono-, di-, or tri-stearate, or mixtures thereof. The penicillin salt may be the alkali metal salt, e.g. sodium or potassium penicillin; the alkaline earth salt, e.g. calcium or magnesium penicillin; inorganic salts of iron, copper, bismuth, gold and arsenic; organic salt such as procaine penicillin; and ammonium penicillin. The preparations may also be used as ointments.
Participants were asked to complete three tasks while simultaneously pedaling at a sustainable and self-selected pace. The three tasks were: 1) compose and send an email; 2) search a topic on the internet, and 3) complete an on-line questionnaire.